IL21 and metastatic melanoma: In humans, a phase II trial of IL-21 monotherapy as first line treatment for patients with limited-disease metastatic melanoma demonstrated 25% OR with 9 partial responses, a PFS of 4.3 months and median OS of 12.4 months indicating that IL-21 has anti-tumour effects as a single agent [79].